

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date  
22 January 2004 (22.01.2004)

PCT

(10) International Publication Number  
WO 2004/007440 A1

(51) International Patent Classification<sup>7</sup>: C07C 323/44, A61K 51/04 (74) Agents: HAMMETT, Audrey, Grace, Campbell et al.; Amersham plc, Amersham Place, Little Chalfont, Buckinghamshire HP7 9NA (GB).

(21) International Application Number:

PCT/GB2003/003078

(22) International Filing Date: 16 July 2003 (16.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0216621.3 17 July 2002 (17.07.2002) GB

(71) Applicant (for all designated States except US): HAMMERSMITH IMANET LTD [GB/GB]; Cyclotron Building, Hammersmith Campus, DuCane Road, London W12 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BRADY, Frank [GB/GB]; Imaging Research Solutions Ltd, Cyclotron Building, Hammersmith Campus, DuCane Road, London W12 0NN (GB). LUTHRA, Sajinder, Kaur [GB/GB]; Imaging Research Solutions Ltd, Cyclotron Building, Hammersmith Campus, DuCane Road, London W12 0NN (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: IMAGING COMPOUNDS

WO 2004/007440 A1



(57) Abstract: The invention relates to compounds of formula: (I) or a salt or solvate thereof, wherein: R<sup>1</sup> is <sup>-11</sup>CH<sub>2</sub>R<sup>5</sup> or [<sup>18</sup>F]-C<sub>1-4</sub> fluoroalkyl wherein R<sup>5</sup> is hydrogen or C<sub>1-4</sub> alkyl; R<sub>2</sub> is hydrogen or C<sub>1-4</sub> alkyl; R<sup>3</sup> is halo; and R<sup>4</sup> is halo, C<sub>1-4</sub> alkylthio, or C<sub>1-4</sub> alkyl; and their use for imaging central nervous system (CNS) receptors.


## IMAGING COMPOUNDS

5 The present invention relates to the field of medical imaging, in particular to positron emission tomography (PET) and single-photon emission computed tomography (SPECT) and provides compounds and methods for imaging central nervous system (CNS) receptors.

10 The *N*-methyl-D-aspartate (NMDA) receptor is one of the main subtypes of glutamatergic receptors and is widely accepted to play a pivotal role in long term depression, long term potentiation, and developmental neuronal plasticity. NMDA induced excitotoxicity that is due at least partially to overactivation or prolonged stimulation of NMDA receptors has been found in many CNS diseases such as stroke, brain or spinal chord trauma, epilepsy, Alzheimer's disease, and 15 Huntington's disease. A number of compounds have been investigated as potential radioligands for studying the NMDA receptor ion-channel site *in vivo* using PET. However, the majority of these compounds have suffered the disadvantages of poor penetration of the blood brain barrier or high non-specific binding. Therefore, there exists a need for further radioligands for the NMDA 20 receptor.

WO 94/27591 describes certain substituted guanidines and their use for therapy.

25 Accordingly, in one aspect of the present invention, there is provided a compound of formula (I):



or a salt or solvate thereof, wherein:

$R^1$  is  ${}^{11}\text{CH}_2\text{R}^5$  or  $[{}^{18}\text{F}]\text{-C}_{1-4}$  fluoroalkyl wherein  $\text{R}^5$  is hydrogen or  $\text{C}_{1-4}$  alkyl;  
 $R^2$  is hydrogen or  $\text{C}_{1-4}$  alkyl;  
 $R^3$  is halo; and  
 $R^4$  is halo,  $\text{C}_{1-4}$  alkylthio, or  $\text{C}_{1-4}$  alkyl.

5

$R^1$  is, in one aspect, preferably  ${}^{11}\text{CH}_3$ ,  ${}^{11}\text{CH}_2\text{CH}_3$ , or  ${}^{11}\text{CH}_2\text{CH}_2\text{CH}_3$ , and is most preferably  ${}^{11}\text{CH}_3$ .

10 In an alternative aspect,  $R^1$  is preferably  $-\text{CH}_2{}^{18}\text{F}$ ,  $-\text{CH}_2\text{CH}_2{}^{18}\text{F}$ , or  $-\text{CH}_2\text{CH}_2\text{CH}_2{}^{18}\text{F}$ , and is most preferably  $-\text{CH}_2{}^{18}\text{F}$ .


15  $R^2$  is preferably methyl.

$R^3$  is preferably attached to the phenyl ring in the *para*-position relative to the group  $-\text{SR}^2$ , and in a preferred aspect,  $R^3$  is chloro.

20  $R^4$  is preferably attached to the phenyl ring in the *meta*-position relative to the guanidine bridge, and in a preferred aspect,  $R^4$  is  $\text{C}_{1-4}$  alkylthio, more preferably  $-\text{SCH}_3$ .


25

Thus, in a preferred aspect of the invention, there is provided a compound of formula (Ia):



25 or a salt or solvate thereof, wherein  $R^1$ ,  $R^2$ ,  $R^3$ , and  $R^4$  are as defined for the compounds of formula (I).

In a more preferred aspect of the invention, there is provided a compound of formula (Ib):



5 or a salt or solvate thereof, wherein:

$R^4$  is  $C_{1-4}$  alkylthio, preferably –  $SCH_3$ ;

$R^1$  is either  $^{11}CH_3$ ,  $^{11}CH_2CH_3$ , or  $^{11}CH_2CH_2CH_3$  (preferably  $^{11}CH_3$ ), or  $R^1$  is  $-CH_2^{18}F$ ,  $-CH_2CH_2^{18}F$ , or  $-CH_2CH_2CH_2^{18}F$  (preferably –  $CH_2^{18}F$ ).


10 Most preferred compounds of formula (I) include:

(N-(2-chloro-5-(methylthio)phenyl)-N’-(3-methylthio)phenyl)-N-[N-methyl- $^{11}C$ ]-methylguanidine; and

(N-(2-chloro-5-(methylthio)phenyl)-N’-(3-methylthio)phenyl)-N’-[ $^{18}F$ ]-fluoromethylguanidine.

15

According to a further aspect of the present invention, there is provided a compound of formula (Ic):



20 or a salt or solvate thereof, wherein:

$R^{1c}$  is  $C_{1-4}$  alkyl or  $C_{1-4}$  haloalkyl (preferably  $C_{1-4}$  fluoroalkyl);

$R^{2c}$  is hydrogen or  $C_{1-4}$  alkyl (preferably methyl);

$R^{3c}$  is radioiodine (suitably  $^{123}I$ ,  $^{124}I$ ,  $^{125}I$ , or  $^{131}I$ ) ; and

$R^{4c}$  is halo,  $C_{1-4}$  alkylthio, or  $C_{1-4}$  alkyl.

In this aspect of the invention,  $R^{3c}$  is preferably  $^{124}I$  as this radioisotope has utility in PET.

5

Suitable salts according to the invention, include physiologically acceptable acid addition salts such as those derived from mineral acids, for example hydrochloric, hydrobromic, phosphoric, metaphosphoric, nitric and sulphuric acids, and those derived from organic acids, for example tartaric, trifluoroacetic, citric, malic, lactic, 10 fumaric, benzoic, glycollic, gluconic, succinic, methanesulphonic, and para-toluenesulphonic acids.

As demonstrated below, the compounds of formula (I), (Ia), (Ib), and (Ic) have use as radioligands for the NMDA receptor. Therefore, according to a further aspect of 15 the invention, there is provided a compound of formula (I), (Ia), (Ib), or (Ic) as defined above, or a salt or solvate thereof, for use in an *in vivo* diagnostic or imaging method such as PET. Suitably, a compound of formula (I), (Ia), (Ib), or (Ic) as defined above, or a salt or solvate thereof may be used to image the NMDA receptor in healthy human volunteers.

20

Suitably, the compounds of formula (I), (Ia), (Ib), or (Ic) or salt or solvate thereof are useful for *in vivo* imaging of NMDA receptors and thus have utility in the diagnosis of NMDA- mediated disorders, such as stroke, brain or spinal chord trauma, epilepsy, Alzheimer's disease, or Huntington's disease. Accordingly, there 25 is further provided use of a compound of formula (I), (Ia), (Ib), or (Ic) or a salt or solvate thereof in the manufacture of a radiopharmaceutical for the *in vivo* diagnosis or imaging of an NMDA-mediated disease.


In the alternative, there is provided a method for the *in vivo* diagnosis or imaging of 30 NMDA- mediated disease in a subject, preferably a human, comprising administration of a compound of formula (I), (Ia), (Ib), or (Ic) or a salt or solvate thereof. The method is especially preferred for the *in vivo* diagnosis or imaging of

stroke, brain or spinal chord trauma, epilepsy, Alzheimer's disease, or Huntington's disease.

A compound of formula (I), (Ia), (Ib), (Ic) or a salt thereof is preferably administered  
 5 in a radiopharmaceutical formulation comprising the compound of the invention. A "radiopharmaceutical formulation" is defined in the present invention as a formulation comprising compound of formula (I) or a salt thereof in a form suitable for administration to humans. Administration is preferably carried out by injection of the formulation as an aqueous solution. Such a formulation may optionally contain further ingredients such as buffers; pharmaceutically acceptable solubilisers (e.g. cyclodextrins or surfactants such as Pluronic, Tween or phospholipids); pharmaceutically acceptable stabilisers or antioxidants (such as ascorbic acid, gentisic acid or *para*-aminobenzoic acid).

The dose of a compound of formula (I), (Ia), (Ib), (Ic) or a salt thereof will vary  
 15 depending on the exact compound to be administered, the weight of the patient, and other variables as would be apparent to a physician skilled in the art. Generally, the dose would lie in the range 0.1nmol/kg to 50nmol/kg, preferably 1nmol/kg to 5nmol/kg.

A compound of formula (I), (Ia), or (Ib) or a salt or solvate thereof may be prepared  
 20 from the corresponding compound of formula (II):



wherein R<sup>2</sup>, R<sup>3</sup>, and R<sup>4</sup> are as defined for the compound of formula (I), (Ia), or (Ib), by reaction with the appropriate alkylhalide X-<sup>11</sup>CH<sub>2</sub>R<sup>5</sup> or [<sup>18</sup>F]-C<sub>1-4</sub>fluoroalkyl Y  
 25 wherein R<sup>5</sup> is as defined in formula (I), X is halo preferably iodo, and Y is halo, preferably chloro or bromo.

This reaction is preferably carried out in a polar aprotic solvent such as N,N-

dimethylformamide (DMF) or acetonitrile and in the presence of a base, suitably an inorganic base such as potassium carbonate, potassium hydroxide, or sodium hydride, or an organic base such as a trialkylamine, for example triethylamine or diisopropylethylamine.

5


Alternatively, compounds of formula (I) in which R<sup>1</sup> is [<sup>18</sup>F]-C<sub>1-4</sub> fluoroalkyl may be prepared from the corresponding precursor in which the group R<sup>1</sup> contains a leaving group such as mesylate, tosylate, triflate, nonaflate or halo and can be reacted with [<sup>18</sup>F]- fluoride to give the desired compound of formula (I).

10

Compounds of formula (II) may be prepared as described in WO 94/27591 or Hu *et al*, J.Med. Chem. (1997), **40**, 4281-9.

15


A compound of formula (Ic) or a salt or solvate thereof may be prepared from the corresponding compound of formula (III):



wherein R<sup>1c</sup>, R<sup>2c</sup>, and R<sup>4c</sup> are as defined for the compound of (Ic) and R<sup>6c</sup> is C<sub>1-4</sub> alkyl preferably n-butyl, by reaction with an appropriate labelled iodide salt, suitably and alkali metal iodide such as sodium iodide in the presence of an acid such as peracetic acid.

Compounds of formula (III) may be prepared according to Scheme 1:

Scheme 1



wherein R<sup>1c</sup>, R<sup>2c</sup>, and R<sup>4c</sup> are as defined for the compound of formula (III).

5

The invention will now be illustrated by way of the following Examples:

Example 1. Synthesis of (N-(2-chloro-5-(methylthio)phenyl)-N'-(3-methylthio)phenyl)-N-[N-methyl-<sup>11</sup>C] - methylguanidine ("Compound 1")

10 (i) 2-chloro-5-(methylthio)aniline hydrochloride.

To a stirred solution of 2-chloro-5-(methylthio)benzoic acid (5g, 24.67 mmol) in t-butanol (20mL) was added triethylamine (5.25 mL, 37.8 mmol). After stirring briefly, diphenylphosphoryl azide (6mL, 27.60mmol) was added dropwise. The reaction mixture was slowly heated to reflux for 6hours and then cooled to room 15 temperature. The solvent was removed under reduced pressure and the crude reaction mixture was dissolved in tetrahydrofuran (12.5 mL) followed by the addition of 12.5mL trifluoroacetic acid (1:1). The reaction mixture was heated to reflux for 6 hours and the solvent was evaporated after cooling to room

temperature. The reaction mixture was treated with NaOH (25%) to bring the pH to 12 while cooling in an ice water bath. The product was repeatedly extracted into ethylacetate (4 X 25 mL) and the organic layer washed with water (10 mL). The combined extracts were dried over MgSO<sub>4</sub> and concentrated *in vacuo* to afford 5 yellow oil. The product was purified by column chromatography (SiO<sub>2</sub>, gradient of hexanes/EtOAc) and the collected samples dissolved in ether and treated with HCl/ether (10 mL, 1 M) to provide white crystals. The final product was a white solid (3.73g, 87% yield): mp: 180-181°C;  
TLC: hexanes/EtOAc (9:1)  $R_f$ =0.51;  
10 MS (Cl) *m/e* 174 (M+1 for C<sub>7</sub>H<sub>8</sub>CINS) and *m/e* 191 (M+NH<sub>3</sub>);  
<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>)  $\delta$  (ppm) 7.2-6.7 (m, 3H, Ar-H), 6.1 (br.s 2H, NH<sub>2</sub>), 2.5 (s, 3H, S-CH<sub>3</sub>);  
<sup>13</sup>C-NMR (DMSO-d<sub>6</sub>)  $\delta$  (ppm) 138.1 (C-NH<sub>2</sub>, C1), 129.7 (C-S-CH<sub>3</sub>, C5, and C-H, C3), 119.8 (C-H, C4), 118.1 (C-Cl, C2), 116.6 (C-H, C6), 14.6 (S-CH<sub>3</sub>, C7);  
15 IR: 3481.3 cm<sup>-1</sup> (NH<sub>2</sub>), 2600 – 3000 cm<sup>-1</sup> (C-H aromatic, C-H aliphatic stretch), 1480 – 1600 cm<sup>-1</sup> (C=C), 1250 cm<sup>-1</sup> (S-CH<sub>3</sub>), 1116 cm<sup>-1</sup> (C-N), 832 cm<sup>-1</sup> (C-H aromatic).

(ii) 3-(methylthio)phenylcyanamide

20 A solution of cyanogen bromide (1.42g, 13.4 mmol) in anhydrous diethyl ether (8 mL) was added slowly to a stirred solution of 3-(methylthio)aniline (2.72 mL, 21.4 mmol) in anhydrous diethyl ether at 4 °C. After the addition, the reaction mixture was stirred at 24 °C for 12 hours and became a brown solution with a white precipitate. The precipitate was filtered off; the filtrate was washed with aqueous 25 HCl (1 M, 3 x 15 mL) in ether and the organic layer extracted with brine (10 mL). Then the ether solution was dried over MgSO<sub>4</sub>, filtered, and concentrated *in vacuo* to yield a thick liquid. The crude product was further purified by column chromatography (SiO<sub>2</sub>, a gradient of hexanes/CH<sub>2</sub>Cl<sub>2</sub>/EtOAc) to afford 3-(methylthio)phenyl cyanamide (0.7g, 49% yield) as a white solid: m.p. 64-65°C;  
30 TLC dichloromethane/EtOAc (93:7)  $R_f$ =0.54;  
MS (Cl) *m/e* 165 (M+1 for C<sub>8</sub>H<sub>8</sub>N<sub>2</sub>S), 182 (M+NH<sub>4</sub>), 199 (M+NH<sub>4</sub>+NH<sub>3</sub>), 216 (M+NH<sub>4</sub>+NH<sub>3</sub>+NH<sub>3</sub>);

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ (ppm) 7.2-6.7 (m, 4H, Ar-H), 7.5 (br.s, 1H, NH), 2.45 (s, 3H, S-CH<sub>3</sub>);

<sup>13</sup>C-NMR (CDCl<sub>3</sub>) δ (ppm) 140.8 (C-NH, C1), 137.9 (C-SCH<sub>3</sub>, C3), 129.9 (C-H, C5), 121.3 (C-H, C2), 112.9 (C-H, C4), 112.1 (C-H, C6), 111.6 (CN, C7), 15.5 (S-CH<sub>3</sub>, C8);

5 IR: 3050-3172 cm<sup>-1</sup> (C-H aromatic stretch), 2900-3000 cm<sup>-1</sup> (C-H stretch, methyl C-H stretch), 2227 cm<sup>-1</sup> (CN), 1480-1600 cm<sup>-1</sup> (C=C), 1280-1350 cm<sup>-1</sup> (S-CH<sub>3</sub>), 700-800 cm<sup>-1</sup> (C-H aromatic), 600 cm<sup>-1</sup> (C-S stretch).

10 **(iii) N-(2-chloro-5-(methylthio)phenyl)-N'-(methylthio)phenyl)guanidine**

Aluminium chloride (0.67g, 5 mmol) was added to a stirred solution of 3-(methylthio) phenylcyanamide (prepared using methods described in Example 1 (ii)) (0.82g, 5 mmol) in chlorobenzene (8 mL) at 25<sup>0</sup>C. The solution was stirred for 5 min followed by the addition of 2-chloro-5-(methylthio)aniline hydrochloride (prepared using methods described in Example 1 (i)) (1.25g, 6 mmol). The mixture was heated at 120-130<sup>0</sup>C for 6 hours. The reaction mixture was cooled to room temperature and TLC showed that the reaction was completed. The crude product was then filtered, concentrated and then taken by dichloromethane, the resulting solution was washed by 1M aqueous HCl and followed by saline. Afterwards, the crude product was dried over MgSO<sub>4</sub>, filtered, and concentrated *in vacuo* to yield a thick liquid. The crude product was further purified by column chromatography (SiO<sub>2</sub>, a gradient of CH<sub>2</sub>Cl<sub>2</sub>/MeOH) to afford 1.1g N-(2-chloro-5-(methylthio)phenyl)-N'-(methylthio)-phenyl)guanidine, yield 65%.

15 TLC: CH<sub>2</sub>Cl<sub>2</sub>/MeOH (9:1), R<sub>f</sub>=0.36;

20 MS (Cl) *m/e* 338 (M<sup>+</sup>+1 for C<sub>15</sub>H<sub>16</sub>N<sub>3</sub>S<sub>2</sub>Cl).

**(iv) [N-methyl-<sup>11</sup>C] - (N-(2-chloro-5-(methylthio)phenyl)-N'-(3-methylthio)phenyl)-N'-methylguanidine**

30 <sup>[11</sup>C] Iodomethane produced from the <sup>[11</sup>C] CO<sub>2</sub> reaction with LiAlH<sub>4</sub> and HI was distilled into a reaction vial containing the 0.5mg (1.5μmol) precursor, N-(2-chloro-5-(methylthio)phenyl)-N'-(methylthio)phenyl)guanidine (prepared using methods described in Example 1(iii)) in 250μml acetonitrile and 0.6mg sodium hydride (1mg

of 60% NaH dispersion in mineral oil, 25  $\mu$ mol of NaH). The reaction was carried out at 65°C with stirring for 5 minutes and final mixture was directly injected on to a  $\mu$ -Bondapak C-18 column (7.8x300 mm) with a mobile phase of 70%acetonitrile/0.05M ammonium hydrogen phosphate (pH=8.39) at a flow rate of 5 2.5ml/min and  $\lambda$ =254nm. The radioactive peak eluted at 12.36minutes.

Example 2. Synthesis of (N-(2-chloro-5-(methylthio)phenyl)-N'-(3-methylthio)phenyl)-N'-[<sup>18</sup>F]-fluoromethylguanidine.

[<sup>18</sup>F]Fluorobromomethane was prepared from dibromomethane via a nucleophilic 10 substitution reaction using [<sup>18</sup>F] fluoride. Purified from its precursor and solvent mixture by using a silica gel (70-230 mesh) packed column heated at 100°C, [<sup>18</sup>F]Fluorobromomethane was trapped into a vial containing 1mg of precursor (N-(2-chloro-5-(methylthio)phenyl)-N'-(3-methylthio)phenyl)guanidine), 1mg of sodium 15 hydride and 0.5ml of acetonitrile. After trapping, the mixture was allowed to stand at room temperature for 5-10min for alkylation to complete. The final mixture was directly injected on to C-18  $\mu$ -BondaPak column (7.8 X 300mm) with a mobile phase of 70% acetonitrile / 30% 0.05M (NH<sub>4</sub>)<sub>2</sub>HPO<sub>4</sub> (pH=8.39) at a flow rate of 4.0ml/min and  $\lambda$ =254nm. The radiolabelled product peak had a retention time of 5.0 min, identical to that of authentic non-radiolabelled product.

20

Biological Data

Biological data are presented with reference to the following Figure 1 which shows 25 radioactivity concentration (cpm/g tissue)/(injected cpm/g body weight) in two of the sampled brain tissues Figure 1(a) cerebellum or Figure 1(b) prefrontal cortex. In Figure 1(c) the prefrontal cortex data are shown as ratios with the cerebellum data from individual rats, assuming the cerebellum to have low NMDA receptor density (Bowery et al, Br. J. Pharmacol. 93:944-954 (1988)).

Materials and Methods

30 Sixteen adult male Sprague-Dawley rats (body weight 250 - 320 g; mean  $\pm$  SD = 288  $\pm$  25 g) were used in 5 separate experiments. Each rat was injected with  $\sim$ 13 MBq Compound 1, at a specific activity of 103  $\pm$  40 GBq/ $\mu$ mol, via a previously

catheterised tail vein. The associated stable compound was  $0.5 \pm 0.2$  nmol/kg. Discrete samples of arterial blood were collected from 9 of the rats via a previously catheterised tail artery.

Biodistribution

5 Tissues were sampled post-mortem using an established protocol, as described in Hirani et al, *Synapse* 42:164-176 (2001). The radioactivity concentration data obtained at 12 times up to 90 min after radioligand injection were normalised for both amount injected and body weight, giving:- 'uptake units' =  $(\text{cpm/g tissue}) / (\text{injected cpm/g body weight})$ .

10 Metabolite analysis

Plasma samples were injected directly onto a solid phase extraction (SPE) column (C18), with di-ammonium hydrogen phosphate (0.1 M) mobile phase, and the retained radioactivity subsequently injected onto a reverse phase HPLC column (300 x 7.8 mm i.d.,  $\mu$ -Bondapak C18) with a mobile phase of methanol:0.1 M ammonium formate, 70:40 v/v. The eluates were monitored for radioactivity and absorbance at 254 nm. Brain tissues were assayed using the same methodology, excepting that the samples were homogenised and de-proteinated prior to injection onto the HPLC column.

20 **RESULTS**

Blood and Plasma

Following the initial, rapid decrease in radioactivity concentration concomitant with the tissue distribution phase, the radioactivity level in both whole blood and plasma remained at ~0.2 uptake units for the period 5 to 90 min after intravenous injection.

25 The percentage of radioactivity associated with parent decreased rapidly, to ~50% at 10 min and reached ~5% at 90 min.

Biodistribution

Brain.

Full data sets for each tissue sampled are given in Table 1. Following intravenous injection, there was a high extraction of radioactivity into the brain. All tissues showed a further, small increase in Compound 1 content within the first 5 minutes, followed by a gradual decrease. As a result of differential retention, slight

heterogeneity in distribution developed over time. Highest radioactivity concentrations were measured in cortex and hippocampus with lowest values in medulla and cerebellum. The difference was maximal from 40 minutes after intravenous injection of the radioligand. In brain, Compound 1 represented 5 approximately 95% and 90% of the radioactivity, at 20 and 70 minutes, respectively.

Figure 1 illustrates uptake values in (a) cerebellum and (b) prefrontal cortex as a function of time after injection of Compound 1. Assuming that the radioactivity in cerebellum represents free and non-specifically bound Compound 1, Fig 1(c) 10 shows the development of 'specific signal' over the period of the experiment in cortex, with a final ratio of 'total'/'non-specific' of ~1.4.

#### Periphery.

The distribution of radioactivity in rat tissue as a function of time after intravenous injection of Compound 1 are presented in Table 2. The data are suitable for 15 estimation of the Effective Dose Equivalent, for radiation dosimetry purposes.

#### SUMMARY

Compound 1 showed rapid metabolism and clearance from the plasma with high extraction of the radiolabelled parent into rat brain. A specific signal (total/non-specific radioactivity) developed within a time commensurate with PET scanning. 20 The signal was small but this might be expected in 'normal' brain, with a resting state of the NMDA receptor. If the specific signal represents selective binding to a site on the NMDA receptor, the signal should be increased following channel opening.

**Table 1** Distribution of radioactivity in rat brain tissue as a function of time (minutes) after intravenous injection of **Compound 1**.  
 Data are from 1 rat or 2 rats(\*) per time point and are expressed in:-  
 Uptake Units = (cpm/g wet weight tissue)/(injected cpm/g body weight).

Tissue	1	2	5	10	15	20	30	40	50	60	70	90 min
Olfactory bulbs	2.34	2.50	2.18	1.91	1.72	1.46	1.10	0.64	0.58	0.55*	0.31	0.28*
Olfactory tubercles	2.49	2.56	2.42	2.14	1.92	1.73	1.24	0.72	0.65	0.65*	0.36	0.36*
Entorhinal cortex	1.92	2.13	2.16	2.04	1.93	1.80	1.31	0.85	0.75	0.73*	0.41	0.38*
Hypothalamus	2.31	2.29	2.28	2.13	1.85	1.67	1.22	0.76	0.61	0.65*	0.33	0.35*
Thalamus	2.59	2.41	2.59	2.39	2.21	2.01	1.43	0.92	0.85	0.74*	0.40	0.42*
Prefrontal cortex	2.52	2.73	2.67	2.52	2.32	1.94*	1.51	0.93	0.80	0.77*	0.52*	0.45*
Striata	2.13	2.33	2.35	2.17	1.92	1.65*	1.32	0.84	0.69	0.67*	0.46*	0.41*
Somatosensory cortex	2.22	2.56	2.69	2.49	2.24	2.03	1.37	0.88	0.71	0.68*	0.38	0.43*
Hippocampus	1.61	1.73	2.00	1.81	1.74	1.60	1.32	0.86	0.73	0.76*	0.54*	0.46*
Visual cortex	2.46	2.71	3.05	2.80	2.28	2.07	1.55	0.89	0.72	0.73*	0.38	0.44*
Inferior colliculi	3.42	3.65	3.23	2.69	2.22	1.97	1.16	0.64	0.56	0.54*	0.39	0.36
Superior colliculi	2.42	2.64	2.59	2.35	2.01	1.64	1.19	0.65	0.57	0.54*	0.28	0.23
Medulla with Pons	2.18	2.35	2.34	2.26	1.92	1.68	1.26	0.80	0.70	0.67*	0.39	0.39*
Cerebellum	2.21	2.47	2.43	2.08	1.81	1.45*	0.55	0.62	0.55	0.54*	0.38*	0.32*

**Table 2** Distribution of radioactivity in rat tissue as a function of time (minutes) after intravenous injection of Compound 1


Tissue data are from 1 rat or 2 rats(\*) per time point. Blood data are from a composite curve derived from 9 of the rats. Data are expressed in Uptake Units = (cpm/g wet weight tissue)/(injected cpm/g body weight).

Tissue	1	2	5	10	15	20	30	40	50	60	70	90 min
Whole blood	0.59	0.42	0.26	0.21	0.19	0.18	0.19	0.16	0.16	0.17	0.18	0.18
Plasma	0.51	0.37	0.24	0.19	0.17	0.17	0.18	0.16	0.16	0.17	0.18	0.20
Skeletal muscle	1.07	1.14	1.32	1.05	1.07	0.96*	0.68	0.61	0.49*	0.44*	0.44*	0.35*
Skin	0.47	0.54	0.61	0.70	0.51	0.68*	0.75	0.39	0.52	0.46*	0.47*	0.40*
Urine	—	—	11.7	10.9	22.0	10.7*	37.5	27.5	84.5	24.4*	16.9*	46.4*
Fat	0.15	0.18	0.23	0.50	0.75	0.40*	0.71	0.45	0.49	0.79*	0.55*	0.51*
Testis	0.50	0.51	0.56	0.66	0.66	0.73*	0.76	0.74	0.69	0.89*	0.74*	0.79*
Small intestine	3.38	3.87	3.17	2.49	2.79	2.16*	2.30	1.09	1.19	1.29*	1.34*	0.93*
Sm. intestine content	4.96	5.62	6.84	5.31	9.63	6.08*	7.14	3.68	4.03	6.08*	5.41*	3.66*
Large intestine	2.71	3.11	2.73	1.92	1.65	1.27*	1.11	0.66	0.76	1.03*	0.76*	0.61*
Lge. intestine content	0.11	0.21	0.13	0.17	0.03	0.28*	0.36	0.23	0.35	0.44*	0.57*	0.66*
Spleen	3.04	2.65	3.85	4.31	4.46	3.26*	4.75	2.83	2.95	2.98*	2.97*	2.07*
Liver	2.48	1.65	2.95	4.38	6.87	6.47*	7.84	5.76	5.01	5.73*	6.02*	3.85*
Kidney	12.5	10.8	8.70	5.72	4.78	3.19*	2.85	1.79	1.68	1.87*	1.88*	1.50*
Stomach	1.60	1.49	1.26	0.82	2.07	0.67*	1.07	0.45	0.32	0.66*	0.96	0.34*
Lung	56.4	44.5	38.7	35.3	10.7	14.0*	7.48	3.99	5.30	4.10*	4.62*	2.62*
Heart (ventricle)	10.4	8.20	4.27	2.20	1.63	1.10*	0.99	0.63	0.50	0.59*	0.52*	0.40*

Claims

1. A compound of formula (I):

5



or a salt or solvate thereof, wherein:

R<sup>1</sup> is -<sup>11</sup>CH<sub>2</sub>R<sup>5</sup> or [<sup>18</sup>F]-C<sub>1-4</sub> fluoroalkyl wherein R<sup>5</sup> is hydrogen or C<sub>1-4</sub> alkyl;


R<sup>2</sup> is hydrogen or C<sub>1-4</sub> alkyl;

10 R<sup>3</sup> is halo; and

R<sup>4</sup> is halo, C<sub>1-4</sub> alkylthio, or C<sub>1-4</sub> alkyl.


2. A compound according to claim 1 of formula (Ia) :

15



or a salt or solvate thereof, wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, and R<sup>4</sup> are as defined in claim 1.

3. A compound according to claim 1 or 2 of formula (Ib):




or a salt or solvate thereof, wherein:

R<sup>4</sup> is C<sub>1-4</sub> alkylthio;

R<sup>1</sup> is either -<sup>11</sup>CH<sub>3</sub>, -<sup>11</sup>CH<sub>2</sub>CH<sub>3</sub>, or -<sup>11</sup>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub> or R<sup>1</sup> is -CH<sub>2</sub><sup>18</sup>F, -CH<sub>2</sub>CH<sub>2</sub><sup>18</sup>F, or -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub><sup>18</sup>F.

5

4. A compound of formula (Ic):



or a salt or solvate thereof, wherein:

10 R<sup>1c</sup> is C<sub>1-4</sub> alkyl or C<sub>1-4</sub> haloalkyl;

R<sup>2c</sup> is hydrogen or C<sub>1-4</sub> alkyl;

R<sup>3c</sup> is radioiodine (suitably <sup>123</sup>I, <sup>124</sup>I, <sup>125</sup>I, or <sup>131</sup>I); and

R<sup>4c</sup> is halo, C<sub>1-4</sub> alkylthio, or C<sub>1-4</sub> alkyl.

15

5. A compound according to any one of claims 1 to 3 selected from:

(N-(2-chloro-5-(methylthio)phenyl)-N'-(3-methylthio)phenyl)-N-[N-methyl-<sup>11</sup>C]-methylguanidine; and

(N-(2-chloro-5-(methylthio)phenyl)-N'-(3-methylthio)phenyl)-N-[<sup>18</sup>F]-

20 fluoromethylguanidine;

or a salt or solvate thereof.

6. A compound according to any one of claims 1 to 5 for use in an *in vivo* diagnostic or imaging method such as PET.

25

7. Use of a compound according to any one of claims 1 to 5 in the manufacture of a radiopharmaceutical for the *in vivo* diagnosis or imaging of an NMDA-mediated disease.

8. A method for the *in vivo* diagnosis or imaging of NMDA- mediated disease in a subject, preferably a human, comprising administration of a compound according to any one of claims 1 to 5.

5

Fig. 1(a).




Fig. 1(b).





Fig. 1(c).



## INTERNATIONAL SEARCH REPORT

PCT/GB 03/03078

**A. CLASSIFICATION OF SUBJECT MATTER**  
 IPC 7 C07C323/44 A61K51/04 C07B59/00

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
 IPC 7 C07C A61K C07B

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 94 27591 A (CAMBRIDGE NEUROSCIENCE) 8 December 1994 (1994-12-08) cited in the application page 33, line 9 - page 34, line 2; example 57; claim 24 ---	4, 6-8
Y	J. OWENS ET AL: NUCLEAR MEDICINE & BIOLOGY, vol. 27, no. 6, 2000, pages 557-564, XP002254332 the whole document ---	4, 6-8
A	A.R. GIBBS ET AL: JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS, vol. 45, no. 5, April 2002 (2002-04), pages 395-400, XP002254333 the whole document --- -/-	1, 6-8

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

## ° Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

18 September 2003

08/10/2003

Name and mailing address of the ISA  
 European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Van Amsterdam, L

## INTERNATIONAL SEARCH REPORT

PCT/GB 03/03078

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	A. A. WILSON ET AL: J. MED. CHEM., vol. 34, no. 6, 1991, pages 1867-1870, XP002254334 the whole document -----	1,6-8

**INTERNATIONAL SEARCH REPORT**

PCT/GB 03/03078

**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:  
Although claim 8 is directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

Information on patent family members

PCT/GB 03/03078

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9427591	A 08-12-1994	AT	245977 T	15-08-2003
		AU	695337 B2	13-08-1998
		AU	7047394 A	20-12-1994
		CA	2163361 A1	08-12-1994
		CN	1126434 A	10-07-1996
		DE	69432984 D1	04-09-2003
		EP	0705100 A1	10-04-1996
		JP	8510754 T	12-11-1996
		WO	9427591 A1	08-12-1994
		US	6147063 A	14-11-2000
		US	6153604 A	28-11-2000
		ZA	9403744 A	26-04-1995